Now I have a complete picture. Let me write the final consolidated review.

## Summary

ProteinVista introduces a 3D CNN that voxelizes full atomic protein structures at 1 Å resolution using an adaptive boxing strategy, is pre-trained on ~500K AlphaFold-2 structures (contrastively aligned to ESM-2 embeddings), and is evaluated on transporter-substrate prediction (TSP), enzyme-substrate prediction (ESP), and IC50 drug-target affinity prediction. The core finding — that a 123M-parameter 3D CNN can match or outperform sequence-only ESM-2 models on structure-sensitive tasks while being substantially faster at inference — is genuinely interesting and well-supported by the controlled comparison.

## Strengths

- **Adaptive boxing strategy (Section 2.1).** Selecting among four box sizes (64³, 96³, 128³, 160³) that fully enclose each protein directly reduces the memory waste that has historically discouraged 3D CNNs for variable-sized protein structures. This is a simple but practical contribution.
- **Stratification analysis (Section 4.1, Figure 2).** Binning test proteins by sequence identity, TM-score, and pLDDT separately reveals the conditions under which structural information matters. The finding that ProteinVista outperforms ESM-2 specifically in high-identity/high-TM-score bins, while the ensemble helps across all bins, provides concrete evidence for the complementarity thesis rather than just asserting it.
- **Systematic ablation study (Section 4.2).** Testing single-view vs. multi-view inference, resolution, pre-training objective, and augmentation effects on the same IC50 benchmark gives a clear picture of which design choices matter. The finding that training-time augmentation has negligible effect (−0.1%) but multi-view inference matters strongly (−6.4% for single view) is non-obvious and useful.
- **Clean controlled experimental setup (Section 3.1).** All models receive identical prediction heads, same MolFormer embeddings, and same hyperparameter search, isolating the effect of the protein encoder. This is the right methodological approach for fair comparison.
- **Honest reporting of limitations (Section 3.4).** The GO annotation experiment showing ESM-2 outperforming ProteinVista (Fmax 0.57 vs. 0.62) honestly bounds the method's applicability to structure-sensitive tasks, which strengthens scientific credibility.

## Weaknesses

### Fatal
None.

### Major

1. **Pre-training/evaluation data overlap is unexamined.** ProteinVista is pre-trained on >500,000 AlphaFold-2 structures "comprising proteins from the Swiss-Prot database" (Section 2.3). The downstream benchmarks (TSP, ESP, BindingDB) involve well-studied proteins that are overwhelmingly represented in Swiss-Prot. The paper does not check, filter, or discuss overlap between pre-training proteins and downstream test proteins. If a test protein's structure was seen during pre-training, ProteinVista's encoder has been directly optimized on its geometry, while ESM-2's exposure via masked language modeling is qualitatively different. The fix is straightforward — filter the pre-training set to remove any protein whose structure appears in downstream test sets, or at minimum report the overlap and re-run key comparisons on a non-overlapping subset. Without this, the central comparison against ESM-2 rests on uncertain ground.

2. **The SOTA comparison (Table 1) conflates the encoder's contribution with ensembling and pipeline engineering.** The headline result (ESM-ProteinVista_OP beating SPOT on TSP and ProSmith-ESP/Fusion_ESP on ESP) compares an *ensemble of two models* (ProteinVista + ESM-2₆₅₀M) with an *optimized pipeline* (joint fine-tuning of the small-molecule encoder, contrastive network, prediction averaging) against single-model baselines. ProteinVista alone (90.8% TSP accuracy) is below SPOT (92.4%). This conflates two sources of gain: the value of ProteinVista's structural encoder, and the value of ensembling/pipeline engineering. The paper should compare ProteinVista alone (or the simple ensemble) against SPOT/ProSmith-ESP using the same pipeline, so readers can see whether the structural encoder itself achieves SOTA.

### Minor

3. **FLOPs/runtime ratio needs methodological clarification.** ProteinVista is reported at 415 GFLOPs (20 s/1k samples), ESM-2₆₅₀M at 520 GFLOPs (426 s), and ESM-2₁₅₀M at 140 GFLOPs (215 s). A ~20× runtime difference at comparable FLOPs (PV vs. ESM-2₆₅₀M) is larger than architectural differences alone can explain without information about FLOPs counting methodology, batch sizes, and whether the metric is measured with the same profiler across architectures. The runtime advantage itself is meaningful (and supported by the CNN vs. transformer architectural argument), but the FLOPs framing needs explicit justification to support the "compute-efficient" claim in the title.

4. **Rotation augmentation covers only the cubic symmetry group, not arbitrary rotations.** The paper claims "rotation-robust representations" (abstract) and "rotation-invariant predictions" (Section 1), but augmentation is limited to 90° rotations and mirror reflections (48 discrete orientations). There is no evaluation on proteins rotated by angles outside {0°, 90°, 180°, 270°}. A proper evaluation should test on arbitrary rotations sampled from SO(3) to verify whether the learned invariance generalizes beyond the discretely sampled orientations.

5. **Extreme p-value without effect size.** The Wilcoxon signed-rank test yielding p < 10⁻³⁰⁴ for the IC50 comparison (Section 3.2) is effectively zero. This either indicates a computation error or a sample size so large that any tiny difference attains significance. Reporting effect size (e.g., Cohen's d or median paired difference) and the test sample size would be far more informative.

6. **No variance or error bars on main results (Tables 1 and 2).** All metrics are reported as single-point estimates. Given variance from random augmentation, pre-training stochasticity, and fine-tuning initialization, reporting mean and standard deviation over multiple runs would substantially strengthen the reliability of the conclusions. The ablation study (Section 4.2) demonstrates the authors can compute relative changes — similar rigor should apply to the main results.

7. **Ensemble degradation on IC50 needs diagnosis.** The ESM-ProteinVista ensemble achieves 0.68 R² while ProteinVista alone achieves 0.69 R² (Table 2). If the sequence model adds nothing, the ensemble should match ProteinVista, not degrade. This suggests a calibration or scaling mismatch between the two models' predictions that should be investigated (e.g., with softmax-temperature or Platt scaling before averaging).

### Trivial

8. Dataset sizes (n for each benchmark) are only in Table S3 of the supplementary, not the main text.

9. Only five heavy atom types (C, N, O, S, P) are voxelized; metals in metalloproteins and halogen atoms in modified residues are excluded. The paper should state this limitation and discuss its potential impact.

## Nice-to-Haves

- Report runtimes and FLOPs with the same profiler for both architecture types, with batch sizes and GPU memory utilization.
- Compare ProteinVista alone (not the ensemble) against SPOT/ProSmith-ESP using the same optimized pipeline, to isolate the encoder's standalone SOTA contribution.
- Test rotation robustness on proteins rotated by arbitrary angles (not just the cubic symmetry group).
- Diagnose the IC50 ensemble degradation with temperature scaling before averaging predictions.

## Removed Points

These points are flagged to be removed from the harsh critic input, treated with caution:

- **Pre-training objective tension (HC Weakness 4).** The critic argued that contrastive alignment with ESM-2 embeddings is in tension with attributing gains to "explicit 3D pocket geometry." However, the paper's own ablation (Section 4.2) directly addresses this: Rosetta-score regression (purely structural, no ESM-2) is only 1.0% behind contrastive pre-training. Both objectives produce competitive encoders, and the paper transparently reports this. The claimed tension is largely manufactured; the paper frames the choice empirically.

- **"First compute-efficient full-atom 3D CNN" overclaim (HC Section-by-Section).** The critic notes prior work (DeepSite, EnzyNet, 3DCNN_MQA). The paper's actual formulation specifies "pretrained on large-scale AlphaFold-2 structures" as the distinguishing factor. The novelty claim is adequately scoped.

- **Missing hydrogen atoms (HC Section-by-Section).** The paper explicitly limits to heavy atoms at 1.0 Å resolution, which is standard practice. Implied by the design choice.

- **Storage comparison understates practical challenge (HC Section-by-Section).** The paper already reports the storage trade-off fairly; this does not threaten any core claim.

- **General "the evaluation lacks rigor" / "baselines may not be fair" without concrete anchor (from HC's sweeping language).** These were properly reduced to the specific, verifiable issues above (data overlap, SOTA comparison, FLOPs methodology).

## Novel Insights

The most interesting finding from this review process is the tension between the paper's two comparison strategies. The direct controlled comparison (ProteinVista vs. ESM-2 on identical pipeline) is well-executed and supports the paper's core claim. But the SOTA comparison (ESM-ProteinVista_OP ensemble vs. single models) uses a fundamentally different evaluation paradigm that undermines the very isolation strategy the controlled comparison was designed to achieve. This suggests the paper would be stronger by fully committing to the controlled-comparison framing and either dropping the SOTA ensemble claim or executing it with properly matched baselines (ensemble vs. ensemble, optimized pipeline vs. optimized pipeline).

## Suggestions

1. **Filter the pre-training set** to remove any protein whose structure appears in downstream test sets, or at minimum report the overlap and re-run key comparisons on a non-overlapping subset. This is the single highest-impact change the authors can make.
2. **Report ProteinVista alone** (not the ensemble) against SPOT and ProSmith-ESP using the same optimized pipeline, so the reader can assess the encoder's standalone SOTA contribution.
3. **Specify FLOPs measurement methodology** (profiler tool, batch sizes, operation count definition) and report multiply-accumulate counts consistently for both architectures.
4. **Include variance estimates** (mean ± std over at least 3 runs) for all main results in Tables 1 and 2.
5. **Report effect size** alongside p-values for the IC50 comparison (e.g., Cohen's d or median paired difference).
6. **Test rotation robustness** on proteins rotated by arbitrary angles outside the cubic symmetry group.
7. **Diagnose the IC50 ensemble degradation** with temperature scaling before averaging.

## Score and Decision

**Calibration anchors used (all rounds):** I retrieved 24 candidate anchors across 6 score bands. The most informative comparisons are:

| Anchor | Avg Score | Round | Itemized? | Comparison |
|--------|-----------|-------|-----------|------------|
| ProteiNexus (iBAWiEjogY) | 3.67 | Bracket | Yes | Similar data-leakage weakness but weaker overall (less controlled setup, no stratification analysis). Our paper is clearly stronger. |
| msESM (MBIGXMT0qC) | 5.00 | Bracket | Yes | Marginal improvements over baselines; rejected for limited novelty. Our paper has clearer evidence. |
| E³former (QKywN4BbqA) | 5.25 | Narrow | Yes | Strong method but unconvincing core motivation; rejected 6,6,6,3. Our paper's motivation is well-grounded. |
| Pre-train Seq/Struct/Surf (BEH4mGo7zP) | 5.75 | Narrow | Yes | Modest improvements but accepted. Our paper has more convincing controlled experiments. |
| AtomSurf (ARQIJXFcTH) | 6.75 | Bracket | Yes | More rigorous benchmark adherence and cleaner comparisons. Our paper has stronger core contributions but weaker SOTA framing. |

**Initial bracket:** After filtering, I placed the paper in the 5.5–7.5 band based on the strength of its controlled experiments and the presence of two verifiable methodological concerns (data overlap, SOTA comparison framing).

**Narrowing:** Comparing favorability-rated items: our paper's strengths (9.47–14.37) are comparable to accepted anchors in the 5.75–6.75 range. The two Major weaknesses (favorability -0.27, -0.11) are mildly negative — less damaging than the fatal issues that drove ProteiNexus (3.67) down, but more concerning than AtomSurf's missing-baseline issue (favorability 3.74). Our paper lacks the rigor in benchmark comparisons that AtomSurf (6.75) provides, but has stronger core contributions than the 5.0–5.75 papers. **Final score: 6.0.**

MY FINAL SCORE: <score>6.0</score>
MY FINAL DECISION: <decision>Accept</decision>